Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

You may be eligible if

• 1. Subjects who aged 18 years or older
• 2. Subjects whose written informed consent was obtained complying with the local regulatory requirements prior to their participation in the trial
• 3. Subjects who have histologically or cytologically confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas. High-quality contrast-enhanced CT scanning is required to evaluate resectability. Measurable disease is not required.
• 4. Subjects with no other malignancy diagnosed within past five years except for:
• * Cured non-melanoma skin cancer
• * Cured cervical intraepithelial neoplasia (CIN)
• * Cured In-situ cervical cancer (CIS)
• 5. Subjects who are ECOG performance status of ≤ 1